<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069055</url>
  </required_header>
  <id_info>
    <org_study_id>HerniaAnalgesia2010-001</org_study_id>
    <nct_id>NCT01069055</nct_id>
  </id_info>
  <brief_title>Comparison of Lornoxicam and Paracetamol for Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair</brief_title>
  <official_title>Pre-emptive Intravenous Analgesia for Elective Inguinal Hernia Repair: Prospective Randomized Double-blinded Placebo Controlled Comparison of Lornoxicam and Paracetamol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diskapi Teaching and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diskapi Teaching and Research Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lornoxicam or paracetamol is more effective&#xD;
      in providing pre-emptive analgesia for adult patients undergoing elective unilateral inguinal&#xD;
      hernia repair under general anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early postoperative pain is the major cause that may restric physical activity of the&#xD;
      patients and delay in returning work. Newer non-steroid analgesic drugs (NSAD) can be helpful&#xD;
      in overcoming this problem, especially in pre-emptive use. In this prospective randomized&#xD;
      placebo controlled double blinded study we aimed to determine whether lornoxicam, as a NSAD,&#xD;
      or paracetamol is more effective in providing pre-emptive analgesia for patients undergo&#xD;
      elective unilateral inguinal hernai repair under general anesthesia. 60 patients above the&#xD;
      age of 18, ASA score of I to III will be assigned into 3 groups. All the patients will be&#xD;
      operated under general anesthesia. Recurrent hernia cases, pregnant or lactated women,&#xD;
      patients allergic to the two drugs, patients with documented gastric disorders or bleeding&#xD;
      disorder or under anticoagulent therapy will be excluded.&#xD;
&#xD;
      Group designs:&#xD;
&#xD;
      Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.&#xD;
&#xD;
      Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the&#xD;
      surgery.&#xD;
&#xD;
      Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the&#xD;
      surgery.&#xD;
&#xD;
      All patients will receive patient controlled intravenous analgesia with morphine for 24 hours&#xD;
      postoperatively.&#xD;
&#xD;
      Postoperative pain levels will be determined by VAS (visual analog scale) and morphine&#xD;
      consumption will be recorded.&#xD;
&#xD;
      Patients will be prescribed with oral paracetamol (300 mg) plus codein (15 mg)at discharge at&#xD;
      the end first 24 hours.&#xD;
&#xD;
      Patients will be asked to record daily consumption of given analgesic, pain response to&#xD;
      physical activity by using Likert scale, and VAS scores daily.&#xD;
&#xD;
      The first follow-up examination will take place on day-7. The patients will be asked to keep&#xD;
      recording the same parameters until the second hospital visit at 4th week.&#xD;
&#xD;
      On the follow-up examination at 4th week quality of life will be determined by SF-36 form.&#xD;
&#xD;
      The results will be analyzed using SPSS for Windows software.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain and comfort</measure>
    <time_frame>24 and 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative late pain complaint and quality of life</measure>
    <time_frame>4. week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Inguinal Hernia</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group I (Placebo Control) 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lornoxicam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sterile Saline</intervention_name>
    <description>Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous lornoxicam</intervention_name>
    <description>Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.</description>
    <arm_group_label>Lornoxicam</arm_group_label>
    <other_name>Lornoxicam: Xefo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous paracetamol</intervention_name>
    <description>Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>Paracetamol: Perfalgan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  inguinal hernia&#xD;
&#xD;
          -  unilateral hernia&#xD;
&#xD;
          -  general anesthesia&#xD;
&#xD;
          -  elective repair&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  drug allergy&#xD;
&#xD;
          -  bilateral hernia&#xD;
&#xD;
          -  local anesthesia&#xD;
&#xD;
          -  local blockade&#xD;
&#xD;
          -  regional anesthesia&#xD;
&#xD;
          -  emergency surgery&#xD;
&#xD;
          -  complicated hernia&#xD;
&#xD;
          -  recurrent hernia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ercan Sonmez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diskapi Teaching and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diskapi Teaching and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Alp Alptekin, MD</last_name>
      <phone>+90 312 5962370</phone>
      <email>alptekinmd@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Hakan Kulacoglu, MD, FACS</last_name>
      <email>hakankulacoglu@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>February 23, 2010</last_update_submitted>
  <last_update_submitted_qc>February 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Diskapi Teaching and Research Hospital</name_title>
    <organization>Ministry of Health</organization>
  </responsible_party>
  <keyword>inguinal hernia</keyword>
  <keyword>surgery</keyword>
  <keyword>general anesthesia</keyword>
  <keyword>analgesia</keyword>
  <keyword>pre-emptive</keyword>
  <keyword>SF36</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Lornoxicam</mesh_term>
    <mesh_term>Piroxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

